XELJANZ (Pfizer Australia Pty Ltd)
Product name
XELJANZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
195 working days (255)
Active ingredients
tofacitinib citrate
Registration type
EOI
Indication
XELJANZ (film coated tablets) is now also indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological therapy.